Healthcare Industry News: bladder cancer
News Release - March 19, 2007
Spectrum Pharmaceuticals Bolsters Ozarelix Team with Addition of In-House Urology Expert Bela S. Denes, MD, FACSThought Leader With 30+ Years Experience
Associated With Development of Drugs in BPH and Other Urology Indications
In Addition to Ozarelix, Will Assist with EOquin(R), a Drug Entering Phase 3 for bladder cancer
IRVINE, Calif., March 19 (HSMN NewsFeed) -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI ) today announced the addition of Bela S. Denes, MD, FACS to the ozarelix development team as Senior Director of Clinical Research and Development. Ozarelix is currently in a Phase 2b clinical trial in patients with benign prostate hypertrophy (BPH).
"Dr. Denes brings to our team more than 30 years of experience in the field of urology, including the clinic, the lab, as an investigator, as a clinical research program director, and as a practicing physician," said Rajesh Shrotriya, M.D., Chairman, President and CEO of Spectrum Pharmaceuticals. "We believe that Dr. Denes' experience with developing treatments for BPH will be invaluable as we advance ozarelix into late-stage, pivotal trials as early as the end of this year. Dr. Denes will also assist with the clinical development of EOquin in bladder cancer. We announced last week that we reached a Special Protocol Assessment agreement with the FDA for EOquin and will begin Phase 3 clinical trials shortly."
Most recently, Dr. Denes served as the Director of Clinical Research with Lilly/ICOS, and was involved with the clinical development and launch of Cialis® (tadalafil). Prior to his tenure at Lilly/ICOS, Dr. Denes spent 23 years in clinical practice and as an Associate Professor of Urology at St. Louis University and served on many advisory boards. During this time, he gained broad experience in diseases of the prostate including BPH, prostate cancer, bladder cancer, overactive bladder and erectile dysfunction. Dr. Denes is Board Certified by the American Board of Urology and a member of the American College of Surgeons. Dr. Denes completed his medical school and residency training at Washington University in St. Louis.
Ozarelix Phase 2 Data
In late 2006, Spectrum reported highly statistically significant results in favor of ozarelix from a double-blinded, randomized, placebo-controlled, multi-center, dose ranging Phase 2 trial in patients suffering from BPH. Results from that trial were used to support an Investigational New Drug application (IND) with the FDA. Following the acceptance of the IND by the FDA in January 2007, a randomized, placebo-controlled Phase 2b trial of ozarelix enrolling approximately 75 men suffering from BPH was initiated. To date, 45 patients have been enrolled in the trial, and data from this Phase 2b trial is expected to be available in the second half of 2007, with safety and efficacy data expected to be used to support a New Drug Application (NDA) for ozarelix. A Phase 3 trial of ozarelix in BPH is expected to begin enrollment in the second half of 2007.
About Ozarelix and Development Alliance with AEterna Zentaris
Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist administered as an intramuscular injection. In August 2004, Spectrum received an exclusive license from AEterna Zentaris to develop and market ozarelix for all potential indications in North America (including Canada and Mexico) and India.
In addition, Spectrum will receive 50 percent of any upfront and milestone payments, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology indications have recently been licensed to Nippon Kayaku, a key player in the Japanese oncology market.
Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent prostate cancer and other indications.
About Benign Prostatic Hypertrophy
Benign prostatic hypertrophy is a non-cancerous enlargement of the prostate frequently occurring in men over the age of 50. According to the National Institutes of Health, BPH affects more than 50% of men over the age of 60 and as many as 90% of men over the age of 70 and it is estimated that there are currently more than 28 million men suffering from BPH in the United States.
The IPSS (also known as AUA symptom index) is a standardized scoring system which evaluates the seven principal symptoms of BPH. The enlargement can result in the gradual squeezing of the urethra, resulting in increased frequency or difficulty in urinating. Treatment options for BPH include surgery and medications to reduce the amount of tissue and increase the flow of urine. Current treatment options have limited efficacy, leading to inadequate compliance. Medications currently available belong to two classes: alpha blockers (such as FLOMAX®, CARDURA® and HYTRIN®) which relax the muscles in the neck of the bladder and in the prostate, but have no direct effect on the prostate growth itself, and alpha reductase inhibitors (such as PROSCAR® and AVODART®), which can result in some reduction of the prostate size but have a very slow onset of action, and may be associated with impotence and decreased libido.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, our team's ability to identify promising drugs and move these drugs through development and toward commercialization, advancing ozarelix into late-stage, pivotal trials as early as the end of this year, that data from this Phase 2b trial is expected to be available in the second half of 2007, that a Phase 3 trial of ozarelix in BPH is expected to begin enrollment in the second half of 2007, the safety and efficacy of ozarelix and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that price and other competitive pressures may make the marketing and sale of our generic drugs not commercially feasible, the possibility that our efforts to acquire or in- license and develop additional drug candidates may fail, our lack of revenues, our limited experience in establishing strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
 FLOMAX is a registered trademark of Boehringer Ingelheim
 CARDURA is a registered trademark of Pfizer, Inc.
 HYTRIN is a registered trademark of Abbott Laboratories
 PROSCAR is a registered trademark of MERCK & CO., Inc.
 AVODART is a registered trademark of GlaxoSmithKline
 CIALIS is a registered trademark of Lilly ICOS LLC
Source: Spectrum Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.